| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On June 4, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1977N-0094L
|
| Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Use; Proposed Amendment ot the Tentative Final Monograph; Required Warnings and Other Labeling
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
|
|
| 2005D-0112
|
| Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006P-0090
|
| Immediately begin the phased removal from the market of propoxyphene (Darvon) and all propoxyphene-containing products.
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0498
|
| Use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods
|
|
|
|
|
| 2007D-0020
|
| Medical Devices: Class II Special Controls Guidance Document: Oxygen Pressure Regulators and Oxygen Conserving Devices
|
|
| |
|
| 1977N-0094L
|
| Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Use; Proposed Amendment ot the Tentative Final Monograph; Required Warnings and Other Labeling
|
|
|
|
|
|
| |
|
|
|
| C 8
|
| Arnold & Porter
|
| Vol #:
|
| 25
|
|
|
|
|
| C 9
|
| Pain Care Coalition
|
| Vol #:
|
| 1
|
|
|
|
|
| C 10
|
| Bayer HealthCare
|
| Vol #:
|
| 1
|
|
|
|
|
| C 11
|
| American Academy of Pediatrics
|
| Vol #:
|
| 1
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET 19910
|
| Bodyhealth.com Corporation
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19911
|
| Boots Retail USA Inc.
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19912
|
| Common Sense Nutrition Company
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19913
|
| Weleda, Inc.
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19914
|
| Weleda, Inc.
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19915
|
| AdvoCare International, L.P.
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19916
|
| Nature's Answer
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19917
|
| Nature's Answer
|
| Vol #:
|
| 175
|
|
|
|
|
| LET 19918
|
| Bradley Pharmaceuticals, Inc.
|
| Vol #:
|
| 175
|
|
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
|
|
| C 1028
|
| R. Grolitzer
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1029
|
| K. Cappa
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1030
|
| C. Smith
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1031
|
| L. Lindsay
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1032
|
| P. Wu
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1033
|
| A. Soto
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1034
|
| J. MaComb
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1035
|
| J. Patronagio
|
| Vol #:
|
| 68
|
|
| | | | | | | | |
|
| |
|
| C 1110
|
| S. Holmberg
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1111
|
| T. Uguccioni
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1112
|
| G. Robbins
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1113
|
| J. Gurley
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1114
|
| A. Bicknese
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1115
|
| N. Fischer
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1116
|
| D. McCullough
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1117
|
| L. Waybrant
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1118
|
| G. Bosco
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1119
|
| L. Liebersbach
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1120
|
| S. Doerfler
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1121
|
| L. Shafer
|
| Vol #:
|
| 68
|
|
|
|
|
| C 1122
|
| M. Hammett
|
| Vol #:
|
| 68
|
|
|
|
|
| 2005D-0112
|
| Guidance for Industry on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
|
|
|
|
|
| C 7
|
| G. Dohse
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| C 18311
|
| G. Gregg
|
| Vol #:
|
| 198
|
|
|
|
|
| 2006P-0090
|
| Immediately begin the phased removal from the market of propoxyphene (Darvon) and all propoxyphene-containing products.
|
|
|
|
|
| C 2
|
| W. Jonasson
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 98
|
| S. Deren
|
| Vol #:
|
| 7
|
|
|
|
|
| 2006P-0498
|
| Use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods
| |
|
|
|
| LET 1
|
| FDA/CFSAN
|
| Vol #:
|
| 4
|
|
|
|
|
| 2007D-0020
|
| Medical Devices: Class II Special Controls Guidance Document: Oxygen Pressure Regulators and Oxygen Conserving Devices
|
|
|
|
|
| C 2
|
| Allied Healthcare Products, Inc.
|
| Vol #:
|
| 1
|
|
